Valeant amps up its Allergan bid; FDA gets into details on UDI rule;

@FierceMedDev: Volcano grabs ArtheroMed for up to $130M. News | Follow @FierceMedDev

@VarunSaxena2: RT from FierceMedicalDevices: FDA says recalled pediatric nasal prongs potentially deadly. Story | Follow @VarunSaxena2

@MichaelGFierce: 'Nanodaisies' carry two cancer drugs and protect them in the bloodstream. FierceDrugDelivery story | Follow @MichaelGFierce

@EmilyWFierce: $PFE, $FRX and $LLY dominate top 10 ranking of psych meds. More from FiercePharmaMarketing | Follow @EmilyWFierce

> Valeant ($VRX), owner of Bausch + Lomb, increased its offer for Allergan ($AGN) to about $49.4 billion, or $166 per share. News

> The FDA has released new guidelines on how companies can request exceptions from the unique device identifier rule. More

Biotech News

@FierceBiotech: Turn on, tune in, tweet out for upcoming chat on CAR-T with @JohnCFierce & @PennMedicine's David Porter. #FierceASCO. Editor's Corner | Follow @FierceBiotech

@JohnCFierce: Fast biotech -- Upstart Spark grabs a $73M round to back rapid expansion, PhIII study - gene therapy. News | Follow @JohnCFierce

@DamianFierce: Per @Real_MNA, Stryker not bidding on Smith & Nephew but reserves right to do so within 6 mths. Palpable excitement for more UK takeover confusion. | Follow @DamianFierce

@EmilyMFierce: Pace of new MERS infections in Saudi Arabia slows to four a day. More from Reuters | Follow @EmilyMFierce

> Bayer taps Dutch antibody specialist for biologics discovery. More

> Slumping Array aligns with Biogen on early autoimmune R&D. Article

> Valeant dials up its Allergan bid and throws in some R&D promises. Story

> Troubled Trimel touts effect of its female sexual disorder drug Tefina. Report

Pharma News

@FiercePharma: Top-read Tues: With the Pfizer-AstraZeneca soap opera canceled, time for second-guessing. Story | Follow @FiercePharma

@TracyStaton: ICYMI, FiercePharma's top weekend news: FDA-nixed diabetes med from Lilly, Boehringer faces rough path to stardom. Story | Follow @TracyStaton

@EricPFierce: ICYMI: Takeda now 5 for 6 in defending Actos cases at trial. Article | Follow @EricPFierce

@CarlyHFierce: GSK officially under investigation by Britain's Serious Fraud Office. Release | Follow @CarlyHFierce

> Cancer drugs beware: Docs to get monthly paybacks for sticking to preferred meds. More

> U.K. fraud police launch GlaxoSmithKline probe in wake of China corruption charges. Article

Drug Delivery News

> PolyTherics picks up Canadian delivery tech for targeted cancer treatment. Article

> Stentys releases data, says CE mark for sirolimus-eluting stent likely. More

> 'Nanodaisies' carry two cancer drugs and protect them in the bloodstream. Story

> Mannkind: Approval of inhaled insulin drug around the corner. Report

> Swiss team develops imaging technique to aid drug delivery in constricted blood vessels. Item

Diagnostics News

> FDA OK's Qiagen companion Dx for use with Amgen colon cancer drug. News

> Roche, undaunted by reimbursement cutbacks, sees no need for Dx price reductions. Report

> In a first, Immucor wins FDA approval for a blood transfusion molecular Dx test. More

> iRhythm has CE mark in sight for arrhythmia Dx patch. Article

> Chinese scientists create viable paper Dx for hepatitis C virus. Story

Pharma Marketing News

> Sanofi, Lilly hook up to switch impotence remedy Cialis to OTC. Story

> J&J launches 'quantified self' app to game patients into better behavior. Article

> Takeda's colitis med Entyvio wins European OK on heels of FDA's approval. Item

> Sanofi's new MS med scores a spot on U.K.'s NHS formulary. More

> Pfizer, Forest and Lilly dominate top 10 ranking of psych meds. Story

> Got a problem, doc? In Eli Lilly's brave new sales world, that's a plus. Article

Suggested Articles

LabCorp, Philips and Mount Sinai are coming together to develop an AI-driven pathology center of excellence, aimed initially at cancer diagnosis.

The FDA followed through with plans to end its Alternative Summary Reporting program, making 20 years’ worth of device safety data publicly available.

Janssen tapped Resolution Bioscience to develop a companion diagnostic for Zejula in patients with metastatic castration-resistant prostate cancer.